Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 40

Sort by

Sort Order Select

Journal Articles

Mezigdomide Treatment in Relapsed-Refractory Myeloma Patients Shifts Bone Marrow NK and T Cell Populations from Exhaustion to Activation

Lucia Y Chen, Oliver Van Oekelen, Michael Amatangelo, Tracy T. Chow, Bhaskar Upadhyaya, Alessandro Lagana, Geoffrey Kelly, Seunghee Kim-Schulze, Adolfo Aleman, Antonina Kurtova, Sarah Gooding, Sundar Jagannath, Erin Flynt, Anita K. Gandhi, Udo Oppermann, Anjan Thakurta, Samir Parekh

Blood (2023) 142 (Supplement 1): 4686.

https://doi.org/10.1182/blood-2023-187748

Published: 2023

Journal Articles

Multimodal Single-Cell Transcriptomic and Proteomic Correlatives of Patients Outcomes Following Anti-BCMA Cellular Therapy with Ciltacabtagene Autoleucel (Cilta-cel) in Relapsed Multiple Myeloma

Blood (2023) 142 (Supplement 1): 93.

https://doi.org/10.1182/blood-2023-186395

Published: 2023

Journal Articles

In-Depth Characterization of the High Risk-Associated Tumor Immune Landscape in Multiple Myeloma

Blood (2023) 142 (Supplement 1): 648.

https://doi.org/10.1182/blood-2023-189940

Published: 2023

Journal Articles

Immune Dynamics Associated with Patient Outcomes Identified By Multimodal Single-Cell Analysis in Multiple Myeloma Patients Receiving Talquetamab Monotherapy

Blood (2023) 142 (Supplement 1): 1927.

https://doi.org/10.1182/blood-2023-185308

Published: 2023

Journal Articles

Acquisition of 1pLOH-1qGain Is a Frequent Trajectory in Expanding Relapsed/Refractory Myeloma Subclones

Naser Ansari-Pour, Mohammad Kazeroun, Evie Fitzsimons, Selina J Chavda, Alessandro Lagana, Erin Flynt, Udo Oppermann, Karthik Ramasamy, Kwee Yong, Sarah Gooding, Anjan Thakurta

Blood (2023) 142 (Supplement 1): 1999.

https://doi.org/10.1182/blood-2023-190584

Published: 2023

Journal Articles

Confirmed Pathogenic Germline Variants in Cancer Predisposition Genes Incidentally Detected in Somatic Genomic Profiling of Multiple Myeloma Patients

Santiago Thibaud, William Genthe, Saoirse Bodnar, Alessandro Lagana, Jane Houldsworth, Ajai Chari, Adriana C Rossi, Cesar Rodriguez, Larysa J Sanchez, Shambavi Richard, Joshua Richter, Kenan Onel, Sundar Jagannath, Tehilla Brander, Samir Parekh

Blood (2023) 142 (Supplement 1): 534.

https://doi.org/10.1182/blood-2023-190878

Published: 2023

Journal Articles

Dysregulation of Cellular Immunity in High-Risk Multiple Myeloma

Selma Bekri, Simone Katz, Geoffrey Kelly, Travis Dawson, Darwin D'Souza, Michael Mason, Alexandre Alloy, Shameek Biswas, Seunghee Kim-Schulze, Sacha Gnjatic, Samir Parekh, Sundar Jagannath, Alessandro Lagana, Hearn Jay Cho

Blood (2023) 142 (Supplement 1): 1942.

https://doi.org/10.1182/blood-2023-189882

Published: 2023

Journal Articles

The genome of IMiD-refractory myeloma

Alessandro Laganà

Blood (2023) 141 (6): 560–561.

https://doi.org/10.1182/blood.2022018461

Published: 2023

Journal Articles

Comprehensive Characterization of Prolonged Unexplained Cytopenias in Relapsed/Refractory Multiple Myeloma Patients Following BCMA-Directed CAR-T Cell Therapy

Blood (2022) 140 (Supplement 1): 614–616.

https://doi.org/10.1182/blood-2022-165646

Published: 2022

Journal Articles

Gain of chr1q Portends Poor Outcomes in Multiple Myeloma Patients Treated with Venetoclax

Alessandro Lagana, Santiago Thibaud, David T. Melnekoff, Paula Restrepo, Violetta Leshchenko, Jonathan McCafferty, Scott Newman, Abbi Kern, David Corrigan, Feras Hantash, Adriana Rossi, Cesar Rodriguez, Larysa Sanchez, Shambavi Richard, Ajai Chari, Hearn J. Cho, Sundar Jagannath, Joshua Richter, Samir Parekh

Blood (2022) 140 (Supplement 1): 4388–4390.

https://doi.org/10.1182/blood-2022-166572

Published: 2022

Journal Articles

(Distinct) origins of IgM myeloma

Alessandro Laganà, Samir Parekh

Blood (2021) 138 (20): 1914–1915.

https://doi.org/10.1182/blood.2021013860

Published: 2021

Journal Articles

Pathogenic Germline Variants in Multiple Myeloma

Santiago Thibaud, Aaron Etra, Ryan Subaran, Zachry Soens, Scott Newman, Rong Chen, Ajai Chari, Hearn Jay Cho, Sundar Jagannath, Deepu Madduri, David T. Melnekoff, Shambavi Richard, Joshua Richter, Larysa Sanchez, Kuan-lin Huang, Alessandro Lagana, Samir Parekh, Kenan Onel

Blood (2021) 138 (Supplement 1): 399.

https://doi.org/10.1182/blood-2021-151495

Published: 2021

Journal Articles

Transcriptomic Correlates of Response to Selinexor in Multiple Myeloma Reveal a Predictive Signature

Paula Restrepo, Sherry Bhalla, Adolfo Aleman, Violetta Leshchenko, Sarita Agte, Yogita Ghodke-Puranik, Joy Jiang, Mark M. Stevens, Deepu Madduri, Joshua Richter, Shambavi Richard, Ajai Chari, Hearn Jay Cho, Sundar Jagannath, Christopher J Walker, Yosef Landesman, Alessandro Lagana, Samir Parekh

Blood (2021) 138 (Supplement 1): 457.

https://doi.org/10.1182/blood-2021-150522

Published: 2021

Journal Articles

Single-Cell Profiling Reveals Contribution of Tumor Extrinsic and Intrinsic Factors to BCMA-Targeted CAR-T Cell Efficacy in Multiple Myeloma

David T. Melnekoff, Yogita Ghodke-Puranik, Oliver Van Oekelen, Adolfo Aleman, Bhaskar Upadhyaya, Robert Sebra, Sundar Jagannath, Alessandro Lagana, Samir Parekh

Blood (2021) 138 (Supplement 1): 326.

https://doi.org/10.1182/blood-2021-150923

Published: 2021

Journal Articles

Clinical Outcomes and Treatment Strategies for Relapsed/Refractory Myeloma Patients after Relapse on BCMA-Targeted CAR T

Oliver Van Oekelen, Tarek H. Mouhieddine, Darren Pan, Megan Metzger, Sarita Agte, Adolfo Aleman, David T. Melnekoff, Guido Lancman, Alessandro Lagana, Shambavi Richard, Larysa Sanchez, Joshua Richter, Hearn Jay Cho, Ajai Chari, Sundar Jagannath, Samir Parekh

Blood (2021) 138 (Supplement 1): 2704.

https://doi.org/10.1182/blood-2021-152243

Published: 2021

Journal Articles

Large-Scale Mass Cytometry Reveals Significant Activation of Innate and Adaptive Immunity in Bone Marrow Tumor Microenvironment of Iberdomide-Treated Myeloma Patients

Oliver Van Oekelen, Michael Amatangelo, Manman Guo, Bhaskar Upadhyaya, Geoffrey Kelly, Manishkumar Patel, Seunghee Kim-Schulze, Alessandro Lagana, Sarah Gooding, Sundar Jagannath, William E. Pierceall, Udo Oppermann, Samir Parekh, Anjan Thakurta

Blood (2021) 138 (Supplement 1): 730.

https://doi.org/10.1182/blood-2021-151542

Published: 2021

Journal Articles

Title: Genomic and Systemic Metabolism Differences Associated with Racial Disparities in Multiple Myeloma

Emily Gallagher, Alessandro Lagana, Jasmine Huang, David T. Melnekoff, Sundar Jagannath, Samir Parekh

Blood (2021) 138 (Supplement 1): 1601.

https://doi.org/10.1182/blood-2021-150977

Published: 2021

Journal Articles

Aberrant Cell Cycle Programming Confers Rapid Lethality in the EuSOX11+ CCND1 MCL Mouse Model

Donna R Edwards, MPH, PhD, Pei-yu Kuo, MS, Alessandro Lagana, PhD, Seongjee Park, Pavithra Nedumaran, MS, Violetta Leshchenko, PhD, Stephanie Christie, PhD, Shashidhar Jatiani, PhD, Julie Teruya-Feldstein, MD, Samir Parekh, MD

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-143038

Published: 2020

Journal Articles

ADAR1 Drives Disease Progression in Multiple Myeloma By Acting Both As an RNA Editor of Specific Transcripts and As a DNA Mutator of Their Cognate Genes

Rafail Nikolaos Tasakis, MSc, BSc, Alessandro Lagana, PhD, Violetta Leshchenko, PhD, David Melnekoff, BS,MS, Itai Beno, PhD, Jonathan J Keats, PhD, Daniel Auclair, Deepu Madduri, MD, Joshua Richter, MD, Ajai Chari, MD, Hearn Jay Cho, MD PhD, Sundar Jagannath, MD, Joel Dudley, PhD, F. Nina Papavasiliou, PhD, Samir Parekh, MD

Blood (2019) 134 (Supplement_1): 3092.

https://doi.org/10.1182/blood-2019-130669

Published: 2019

Journal Articles

A Machine Learning Approach Identifies a 30-Gene Model That Predicts Sensitivity to Selinexor in Multiple Myeloma

Alessandro Lagana, PhD, Sherry Bhalla, Adolfo Aleman, Anna Huo-Chang Mei, MS, Violetta Leshchenko, PhD, Yosef Landesman, PhD, David Melnekoff, BS,MS, Itai Beno, PhD, Deepu Madduri, MD, Joshua R Richter, MD, Ajai Chari, MD, Hearn Jay Cho, MD PhD, Sundar Jagannath, MD, Joel Dudley, PhD, Samir Parekh, MD

Blood (2019) 134 (Supplement_1): 3101.

https://doi.org/10.1182/blood-2019-130753

Published: 2019

NARROW

Mezigdomide Treatment in Relapsed-Refractory Myeloma Patients Shifts Bone Marrow NK and T Cell Populations from Exhaustion to Activation

Multimodal Single-Cell Transcriptomic and Proteomic Correlatives of Patients Outcomes Following Anti-BCMA Cellular Therapy with Ciltacabtagene Autoleucel (Cilta-cel) in Relapsed Multiple Myeloma

In-Depth Characterization of the High Risk-Associated Tumor Immune Landscape in Multiple Myeloma

Immune Dynamics Associated with Patient Outcomes Identified By Multimodal Single-Cell Analysis in Multiple Myeloma Patients Receiving Talquetamab Monotherapy

Acquisition of 1pLOH-1qGain Is a Frequent Trajectory in Expanding Relapsed/Refractory Myeloma Subclones

Confirmed Pathogenic Germline Variants in Cancer Predisposition Genes Incidentally Detected in Somatic Genomic Profiling of Multiple Myeloma Patients

Dysregulation of Cellular Immunity in High-Risk Multiple Myeloma

The genome of IMiD-refractory myeloma

Comprehensive Characterization of Prolonged Unexplained Cytopenias in Relapsed/Refractory Multiple Myeloma Patients Following BCMA-Directed CAR-T Cell Therapy

Gain of chr1q Portends Poor Outcomes in Multiple Myeloma Patients Treated with Venetoclax

(Distinct) origins of IgM myeloma

Pathogenic Germline Variants in Multiple Myeloma

Transcriptomic Correlates of Response to Selinexor in Multiple Myeloma Reveal a Predictive Signature

Single-Cell Profiling Reveals Contribution of Tumor Extrinsic and Intrinsic Factors to BCMA-Targeted CAR-T Cell Efficacy in Multiple Myeloma

Clinical Outcomes and Treatment Strategies for Relapsed/Refractory Myeloma Patients after Relapse on BCMA-Targeted CAR T

Large-Scale Mass Cytometry Reveals Significant Activation of Innate and Adaptive Immunity in Bone Marrow Tumor Microenvironment of Iberdomide-Treated Myeloma Patients

Title: Genomic and Systemic Metabolism Differences Associated with Racial Disparities in Multiple Myeloma

Aberrant Cell Cycle Programming Confers Rapid Lethality in the EuSOX11+ CCND1 MCL Mouse Model

ADAR1 Drives Disease Progression in Multiple Myeloma By Acting Both As an RNA Editor of Specific Transcripts and As a DNA Mutator of Their Cognate Genes

A Machine Learning Approach Identifies a 30-Gene Model That Predicts Sensitivity to Selinexor in Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only